
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

MedDay Reports Top-Line Data from Phase III Trial “SPI2”
Details : SPI2 was designed to confirm the results of the first positive Phase III study, MS-SPI, in progressive multiple sclerosis (MS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MD1003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Eurofins CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MD1003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 05, 2020
Lead Product(s) : MD1003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Eurofins CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MD1003
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Eurofins CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MD1003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 05, 2020
Lead Product(s) : MD1003
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Eurofins CDMO
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 14-C MD1003
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 14-C MD1003 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
January 10, 2020
Lead Product(s) : 14-C MD1003
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MD1003
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Parexel | ERT: Clinical Trial Technology Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
Details : MD1003 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 19, 2019
Lead Product(s) : MD1003
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Parexel | ERT: Clinical Trial Technology Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable

Effect of MD1003 in Amyotrophic Lateral Sclerosis
Details : MD1003 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 14, 2017

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Details : MD1003 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 18, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : MD1003
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MD1003-AMN MD1003 in Adrenomyeloneuropathy
Details : MD1003 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Adrenoleukodystrophy.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 11, 2016
Lead Product(s) : MD1003
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Details : MD1003 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 18, 2016

Effect of MD1003 in Spinal Progressive Multiple Sclerosis
Details : MD1003 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2014
